This review considers current approaches to regulatory genotoxicity testing, focusing on how the use of animals can be further replaced, reduced and refined. The complementary roles of in vitro and in vivo testing, and the justification for using animals, are discussed in detail. Recommendations are made for improvements and further work, in the light of the considerable current controversy surrounding the composition and deployment of testing strategies, and the interpretation of the data generated, particularly for carcinogenicity prediction. The major problems are the oversensitivity of in vitro tests and the insensitivity of in vivo assays. On the basis of an analysis of some published databases, it is concluded that there is insufficient support for using in vivo genotoxicity assays for screening. Also, it is questionable whether the scientific benefits of using such assays always outweigh the costs to the animals involved. The considerable efforts being made to harmonise in vivo protocols and to develop improved methods for detecting genotoxicity are discussed. It is recommended that more emphasis be placed on characterising genotoxins in vitro, especially for mechanisms of activity, to optimise the benefits of any confirmatory animal tests.. Also, regulatory agencies are urged to require better-designed and more-scientifically sound protocols, in which animal numbers are minimised and data interpretation, particularly that of negative results, is facilitated. Lastly, in the development and validation of transgenic rodent systems, emphasis should be placed on developing protocols in which other acute toxicity and metabolism endpoints can be measured simultaneously with in vivo mutagenesis, while minimising animal numbers.
BrusickD. (1987). Principles of Genetic Toxicology, 284 pp. New York: Plenum Press.
2.
HartmanP.E. (1989). Early years of the Salmonella mutagen tester strains: lessons from hycanthone.Environmental and Molecular Mutagenesis14, 39–45.
3.
AmesB.N. (1979). Identifying environmental chemicals causing mutations and cancer.Science, New York204, 587–593.
4.
BrusickD. (1994). Genetic toxicology. In Principles and Methods of Toxicology (ed. HayesA.W.), pp. 545–577. New York: Raven Press.
5.
TweatsD. (1994). Mutagenicity. In General and Applied Toxicology (ed. BallantyneB., MarrsT., TurnerP.), pp. 871–936. London: MacMillan.
6.
ScrableH.J., SapienzaC., and CavaneeW.K. (1990). Genetic and epigenetic losses of heterozygosity in cancer predisposition and progression.Advances in Cancer Research54, 25–62.
7.
HoldenH.E. (1982). Comparison of somatic and germ cell models for cytogenetic screening.Journal of Applied Toxicology2, 196–200.
8.
BishopJ.B., and ShelbyM.D. (1990). Mammalian heritable effects research in the National Toxicology Program. In Banbury Report 34: Biology of Mammalian Germ Cell Mutagenesis (ed. AllenJ.W., BridgesB.A., LyonM.F., MosesM.J., RussellL.B.), pp. 425–433. New York: Cold Spring Harbor Laboratory.
9.
VenittS., and ParryJ.M. eds (1984). Mutagenicity Testing: A Practical Approach, 353 pp. Oxford: IRL Press.
10.
KirklandD. ed. (1989). Statistical Evaluation of Mutagenicity Test Data, UKEMS Subcommittee Report on Guidelines for Mutagenicity Testing, Part III, 294 pp. Cambridge: Cambridge University Press.
11.
KirklandD.J. ed. (1990). Basic Mutagenicity Tests: UKEMS Recommended Procedures, UKEMS Subcommittee Report on Guidelines for Mutagenicity Testing, Parti (Revised), 144 pp. Cambridge: Cambridge University Press.
12.
KirklandD.J., and FoxM. eds (1993). Supplementary Mutagenicity Tests: UKEMS Recommended Procedures, UKEMS Subcommittee Report on Guidelines for Mutagenicity Testing, Part III (Revised), 162 pp. Cambridge: Cambridge University Press.
13.
Anon. (1991). Second Report of the FRAME Toxicity Committee. In Animals and Alternatives in Toxicology: Present Status and Future Prospects (ed. BallsM., BridgesJ., SoutheeJ.), pp. 345–375. London: Academic Press and New York: VCH Publishers.
14.
TennantR.W., MargolinB.H., ShelbyM.D., ZeigerE., HasemanJ.K., SpaldingJ., CasparyW., ResnickM., StasiewiczS., AndersonB., and MinorR. (1987). Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays.Science, New York236, 933–941.
15.
ZeigerE., HasemanJ.K., ShelbyM.D., MargolinB.H., and TennantR.W. (1990). Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: confirmation of earlier results with 41 additional chemicals.Environmental and Molecular Mutagenesis16, Suppl. 18, 1–14.
16.
GarnerR.C. (1991). Genotoxicity testing. In Animals and Alternatives in Toxicology: Present Status and Future Prospects (ed. BallsM., BridgesJ., SoutheeJ.), pp. 91–120. London: Academic Press and New York: VCH Publishers.
17.
CombesR.D. (1992). Trends in genotoxicity testing.Chemistry in Industry24, 950–954.
18.
Anon. (1989). Department of Health Guidelines for the Testing of Chemicals for Mutagenicity, 99 pp. London: HMSO.
19.
BridgesB.A. (1976). Short-term screening tests for carcinogens.Nature, London261, 195–200.
20.
AardemaM.J. ed. (1993). Updated worldwide regulatory guidelines for genotoxicity testing: Workshop Proceedings from the 1992 Environmental Mutagen Society Meeting.Environmental and Molecular Mutagenesis21, 1–57.
21.
MasonJ.M., LangenbachR., ShelbyM.D., ZeigerE., and TennantR.W. (1990). Ability of short-term tests to predict carcinogenesis in rodents.Annual Review of Pharmacology and Toxicology30, 149–168.
22.
GatehouseD., RowlandI.R., WilcoxP., CallenderR.D., and ForsterR. (1990). Bacterial mutation assays. In Basic Mutagenicity Tests: UKEMS Recommended Procedures, UKEMS Subcommittee Report on Guidelines for Mutagenicity Testing, Part I (Revised) (ed. KirklandD.J.), pp. 13–61. Cambridge: Cambridge University Press.
23.
CombesR.D. (1992). The in vivo relevance of in vitro genotoxicity assays incorporating enzyme activation systems. In Progress in Drug Metabolism, Vol. 13 (ed. GibsonG.G.), pp. 295–321. London: Taylor and Francis.
24.
BrusickD. ed. (1987). Genotoxicity produced in cultured mammalian cell assays by treatment conditions.Mutation Research189, 1–79.
25.
ZeigerE. (1994). Strategies and philosophies of genotoxicity testing: what is the question?Mutation Research304, 309–314.
26.
RussellW.L. (1990). Problems and possibilities in genetic risk estimation. In Banbury Report 34: Biology of Mammalian Germ Cell Mutagenesis (ed. AllenJ.W., BridgesB.A., LyonM.F., MosesM.J., RussellL.B.), pp. 385–395. New York: Cold Spring Harbor Laboratory.
27.
StraughanD. (1994). First European Commission report on statistics of animal use.ATLA22, 289–292.
28.
Anon. (1994). Report of the Animal Procedures Committee, Cmnd 2730, 32 pp. London: HMSO.
29.
LegatorM.S., and WilliamsD. (1975). The inadequacies of sub-mammalian tests for mutagenicity. In Molecular and Environmental Aspects of Mutagenesis (ed. PrakeshL.), p. 268. Springfield, IL, USA: Thomas.
30.
LegatorM.S., and HarperB.L. (1988). Mutagenicity screening and in vitro testing: the end of an era; animal and human studies: directions for the future.Annals of the New York Academy of Sciences, 534, 833–844.
31.
DearfieldK.L., AulettaA.E., CiminioM.C., and MooreM.M. (1991). Considerations in the US Environmental Protection Agency's testing approach for mutagenicity.Mutation Research258, 259–283.
32.
ElliottB.M., CombesR.D., ElcombeC., GatehouseD., GibsonG.G., and WolfC.R. (1992). Alternatives to Aroclor 1254 for genotoxicity assays: report of the UKEMS Working Party on Enzyme Inducers.Mutagenesis7, 175–177.
33.
ScottD., DeanB.J., DanfordN.D., and KirklandD.J. (1990). Metaphase chromosome aberration assays in vitro. In Basic Mutagenicity Tests: UKEMS Recommended Procedures, UKEMS Subcommittee Report on Guidelines for Mutagenicity Testing, Part I (Revised) (ed. KirlandD.J.), pp. 62–86. Cambridge: Cambridge University Press.
34.
AndersonD. (1994). Cytogenetics. In General and Applied Toxicology (ed. BallantyneB., MarrsT., TurnerP.), pp. 871–936. London: MacMillan.
35.
ParryE.M., HendersonL., and MackayJ.M. (1995). Procedures for the detection of chemically induced aneuploidy: recommendations of a UK Environmental Mutagen Society Working Group.Mutagenesis10, 1–14.
36.
HeddleJ.A., CiminioM.C., HayashiM., RomagnaF., ShelbyM.D., TuckerJ.D., VanparysP., and MacgregorJ.T. (1991). Micro-nuclei as an index of cytogenetic damage: past, present and future.Environmental and Molecular Mutagenesis18, 27–291.
37.
MavourninK.H., BlakeyD.H., CiminioM.C., SalamoneM.F., and HeddleJ. (1990). The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the US Environmental Protection Agency.Mutation Research239, 29–80.
38.
OshimuraM., and BarrettJ.C. (1986). Chemically induced aneuploidy in mammalian cells: mechanisms and biological significance in cancer.Environmental Mutagenesis8, 129–159.
39.
TweatsD. (1994). Follow-up of in vitro positive results. In Proceedings of the Second International Conference on Harmonisation (ed. D'ArcyP.F., & HarronD.W.G.), pp. 240–244. Belfast, Northern Ireland: Queen's University Press.
40.
ShelbyM.D., ErexsonG.L., HookG.J., and TiceR.R. (1993). Evaluation of a three-exposure mouse bone marrow micronucleus protocol: results with 49 chemicals.Environmental and Molecular Mutagenesis21, 160–179.
41.
EhlingU.H. (1991). Genetic risk assessment.Annual Review of Genetics25, 255–280.
42.
HolmstromL.M., PalmerA.K., and FavorJ. (1993). The rodent dominant lethal assay. In Supplementary Mutagenicity Tests: UKEMS Recommended Procedures, UKEMS Subcommittee Report on Guidelines for Mutagenicity Testing, Part III (Revised) (ed. KirklandD.J., FoxM.), pp. 129–156. Cambridge: Cambridge University Press.
43.
AshbyJ. (1989). Origin of current uncertainties in carcinogen/mutagen screening.Environmental and Molecular Mutagenesis14, Suppl. 16, 51–59.
44.
AshbyJ. (1986). The prospects for a simplified and internationally harmonized approach to the detection of possible human carcinogens and mutagens.Mutagenesis1, 3–16.
45.
AshbyJ. (1986). Letter to the Editor.Mutagenesis1, 309–317.
46.
AshbyJ. (1990). Genotoxicity testing: to what extent can it recognise mutagens and carcinogens? In Progress in Predictive Toxicology (ed. ClaysonD.B., MunroI.C., ShubikP., SwenbergJ.A.), pp. 185–205.
47.
AshbyJ. (1993). Gambling and the conduct of genetic toxicology tests.Mutation Research319, 151–153.
48.
AshbyJ. (1994). Propositions in genetic toxicology and their erasure.Mutation Research308, 113–114.
49.
CliveD. (1985). Mutagenicity in drug development: interpretation and significance of test results.Regulatory Toxicology and Pharmacology5, 79–100.
50.
GatehouseD.G., and TweatsD.J. (1986). Letter to the Editor.Mutagenesis1, 307–308.
51.
KirklandD.J., and DeanS.W. (1994). On the need for confirmation of negative genotoxicity results in vitro and on the usefulness of mammalian cell mutation tests in a core battery: experiences of a contract research laboratory.Mutagenesis9, 491–501.
52.
MadleS. (1993). Problem of the harmonisation of philosophies for genotoxicity testing.Mutation Research300, 73–76.
53.
MadleS. (1994). Strategies and philosophies of genotoxicity testing: highly sophisticated versus pragmatic regulatory approaches.Mutation Research308, 111–112.
54.
MendelsohnM.L., MooreD.H., and LohmanP.H.M. (1992). A method for comparing and combining short-term test data: results and interpretation.Mutation Research266, 43–60.
55.
JenssenD., and RamelC. (1980). The micronucleus test as part of a short-term mutagenicity test program for the prediction of carcinogenicity evaluated by 143 agents tested.Mutation Research75, 191–202.
56.
NatarajanA.T., and ObeG. (1986). How do in vivo mammalian assays compare to in vitro assays in their ability to detect mutagens?Mutation Research167, 189–201.
57.
ObeG. (1981). Acetaldehyde not ethanol is mutagenic. In Progress in Mutation Research, Vol. 2 (ed. KappasA.), pp. 19–23. Amsterdam: Elsevier/North-Holland.
58.
LoprienoN., BoncristiG., LoprienoG., and TesoroM. (1991). Data selection and treatment of chemicals tested for genotoxicity and carcinogenicity.Environmental Health Perspectives96, 121–126.
59.
BrownJ.P., and DietrichP.S. (1979). Mutagenicity of plant flavonols in the Salmonella/microsome test: activation of flavonol glycosides by mixed glycosides from rat caecal bacteria and other sources.Mutation Research66, 223–240.
60.
deSerresF.J., and AshbyJ. eds (1981). Progress in Mutation Research, Vol. 1, Evaluation of Short-term Tests for Carcinogens, 827 pp. New York: Elsevier/North-Holland.
61.
IshidateM.Jr., HarnoisM.C., and SofuniT. (1988). A comparative analysis of data on the clastogenicity of 951 chemical substances tested in mammalian cell cultures.Mutation Research195, 151–213.
62.
AshbyJ., deSerresF.J., ShelbyM.D., MargolinB.H., IshidateM.Jr., BeckingG. eds (1988). Evaluation of Short-term Tests for Carcinogens: Report of the International Programme on Chemical Safety's Collaborative Study on In Vivo Assays, 827 pp. Cambridge: Cambridge University Press.
63.
AshbyJ., and TennantR.W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the US NTP.Mutation Research257, 229–306.
64.
KitchenK.T., BrownJ.L., and KulkarniA.P. (1993). Predicting rodent carcinogenicity of Ames test false positives by in vivo biochemical parameters.Mutation Research290, 155–164.
65.
KitchenK.T., BrownJ.L., and KulkarniA.P. (1992). Predictive assay for rodent carcinogenicity using in vivo biochemical parameters: operational characteristics and complementarity.Mutation Research266, 253–272.
66.
KitchenK.T., BrownJ.L., and KulkarniA.P. (1994). Complementarity of genotoxic and non-genotoxic predictors of rodent carcinogenicity.Teratogenesis, Carcinogenesis and Mutagenesis13, 83–100.
67.
MoritaT. (1992). The 6th collaborative study by CSGMT: the MN assay for the top 100 IARC carcinogens: correlation between micronucleus induction and carcinogenesis.Mammalian Mutagenicity Study Group Communications (Japan)5, 19–119.
68.
TiceR.R., and ShelbyM.D. (1994). Report of in vivo subgroup.Mutation Research312, 287–292.
69.
HasemanJ.K., and ClarkA.M. (1990). Carcinogenicity results for 114 laboratory animal studies used to assess the predictivity of four in vitro genetic toxicity assays for rodent carcinogenicity.Environmental and Molecular Mutagenesis16, Suppl. 18, 15–31.
70.
ShimadaH. (1993). Mutagenicity studies of Japanese regulatory guideline: the status quo and the point at issue.Environmental Mutation Research Communications15, 109–121.
71.
AshbyJ., and TennantR.W. (1988). Chemical Structure: Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the US NCI/NTP.Mutation Research204, 17–115.
72.
AshbyJ., and PurchaseI.F.H. (1992). Non-genotoxic carcinogens — an extension of the perspective provided by Perera.Environmental Health Perspectives98, 223–226.
73.
RosenkranzH.S., and KlopmanG. (1993). Structural relationships between mutagenicity, maximum tolerated dose, and carcinogenicity in rodents.Environmental and Molecular Mutagenesis21, 193–206.
74.
TennantR.W. (1993). A perspective on non-mutagenic mechanisms in carcinogenesis.Environmental Health Perspectives, Suppl. 101, 231–236.
75.
ParodiS., MalacarneD., and TaningherM. (1992). Non-genotoxic factors in the carcinogenetic process: problems of detection and hazard evaluation.Toxicology Letters64/65, 621–630.
76.
AshbyJ. (1992). Production of non-genotoxic carcinogenesis.Toxicology Letters64/65, 605–612.
77.
AdlerI-D., & ParryJ.M. (1993). Development of screening tests for aneuploidy induction by environmental pollutants.Environmental Health Perspectives101, 5–9.
78.
MitchellI. de G., LambertT.R., BurdonM., SunderlandJ., PorterR.L., and CarltonJ. (1995). Is polyploidy an important genotoxic lesion?Mutagenesis10, 79–83.
79.
AshbyJ., and LiegibelU. (1992). Transgenic mouse mutation assays: the potential for confusion of genotoxic and non-genotoxic carcinogenesis.Environmental and Molecular Mutagenesis20, 145–147.
80.
EnsleinK., GombarV.K., and BlakeB.W. (1994). Use of SAR in computer-assisted prediction of carcinogenicity and mutagenicity of chemicals by the TOPKAT program.Mutation Research305, 47–62.
81.
SmithingM.P., and DarvasF. (1992). Hazard-expert: an expert system for predicting chemical toxicity. In Food Safety Assessment (ed. FinlayJ.W.), pp. 191–200. Washington: American Chemical Society.
82.
LewisD.F.V., MoereelsH., LakeB.G., IoannidesC., and ParkeD.V. (1994). Molecular modelling of enzymes and receptors involved in carcinogenesis. QSARs and COMPACT-3D.Drug Metabolism Reviews26, 261–285.
83.
KlopmanG., and RosenkranzH.S. (1994). Approaches to SAR in carcinogenesis and mutagenesis. Prediction of carcinogenicity/mutagenicity using MULTI-CASE.Mutation Research305, 33–46.
84.
SandersonD.M., and EarnshawC.G. (1991). Computer prediction of possible toxic action from chemical structure: the DEREK system.Human and Experimental Toxicology10, 261–273.
85.
LangowskiJ. (1993). Computer prediction of toxicity. In Pharmaceutical Manufacturing International (International Review of Pharmaceutical Technology, Research and Development) (ed. BarnacalP.), pp. 77–80. Stirling Publications.
86.
CombesR.D., and JudsonP. (1995). The use of artificial intelligence systems for predicting toxicity.Pesticide Science, in press.
87.
AshbyJ., and PatonD. (1993). The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 different human carcinogen exposures.Mutation Research286, 3–74.
88.
ParryJ.M. (1994). Detecting and predicting the activity of rodent carcinogens.Mutagenesis9, 3–5.
89.
LewisD.F.V. (1994). Comparison between rodent carcinogenicity test results of 44 chemicals and a number of predictive systems.Regulatory Toxicology and Pharmacology20, 215–222.
90.
LongA., and CombesR.D. (1995). Using DEREK to predict the activity of some carcinogens/mutagens found in foods.Toxicology in Vitro, in press.
91.
O'DonovanM.R., FreemantleM.R., HullG., ArlettC.F., and ColeJ. (1994). Extended-term culture of human T lymphocytes: material potentially useful in genotoxicity testing.Toxicology in Vitro8, 651–653.
92.
ReidT., BaldiniA., RandT.C., and WardD.C. (1992). Simultaneous visualisation of seven different DNA probes by in situ hybridisation using combinatorial fluorescence and digital imaging microscopy.Proceedings of the National Academy of Sciences of the United States of America89, 1388–1392.
93.
SavageJ.K., and SimpsonP.J. (1994). FISH “painting” patterns resulting from complex exchanges.Mutation Research312, 51–60.
94.
MullerK., KasperK., and MullerL. (1993). An assessment of the in vitro hepatocyte micro-nucleus assay.Mutation Research292, 213–224.
95.
FritzenschafH., KohlpothM., RuscheB., and SchiffmanD. (1993). Testing of known carcinogens and non-carcinogens in the Syrian hamster embryo (SHE) micronucleus test in vitro; correlations with in vivo micronucleus formation and cell transformation.Mutation Research319, 47–53.
96.
StopperH., KorberC., SchiffmanD., and CasparyW.J. (1993). Cell cycle dependent micronucleus formation and mitotic disturbances in mammalian cells treated with 5-azacytidine.Mutation Research300, 165–177.
97.
MillerB.M., MadleS., and AlbertiniS. (1994). Can a relatively simple screening procedure for the detection of chemicals and aneugenic potential be recommended at the moment?Mutation Research304, 303–307.
98.
NatarajanA.T. (1993). An overview of testing of known or suspected aneugens using mammalian cells in vitro.Mutation Research287, 113–118.
99.
YagiT., SatoM., NishigoriC., and TakebeH. (1994). Similarity in the molecular profile of mutations induced by UV light in shuttle vector plasmids propagated in mouse and human cells.Mutagenesis9, 73–77.
100.
CollinsA.R. (1993). Mutant rodent cell lines sensitive to ultraviolet light, ionizing radiation and cross-linking agents: a comprehensive survey of genetic and biochemical characteristics.Mutation Research293, 99–118.
101.
SkouvJ., RasmussenE.S., FrandsenH., ForchammerJ., & Kryspin-SorensenI. (1995). Activation of c-myc and c-fos proto-oncogenes by the reducing agent DTT (dithiothreitol) in human cells.ATLA23, in press.
102.
RemmelR.P., and BurchellB. (1993). Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions.Biochemical Pharmacology46, 559–566.
103.
DoehmerJ., DograS., FriedbergT., MinierS., AdesnikM., GlattH., and OeschF. (1988). Stable expression of rat cytochrome P450IIB1 cDNA in Chinese hamster cells (V79) and metabolic activation of aflatoxin B1.Proceedings of the National Academy of Sciences of the United States of America85, 5769–5773.
104.
EllardS., MohammedY., DograS., WolfelC., DoehmerJ., and ParryJ.M. (1991). The use of genetically engineered V79 Chinese hamster cultures expressing rat liver CYP1A1, 1A2 and 2B1 cDNAs in micronucleus assays.Mutagenesis6, 461–470.
105.
DaviesR.L., CrespiC.L., RudoK., TurnerT.R., and LangenbachR. (1989). Development of a human cell line by selection and drug metabolising gene transfection with increased capacity to activate promutagens.Carcinogenesis10, 885–892.
106.
CrespiC.L., GonzalezF.J., SteimelD.T., TurnerT.R., GelboinH.V., and PenmanB.W. (1991). A metabolically competent human cell line expressing five cDNAs encoding procarcinogen-activating enzymes; application to mutagenicity testing.Chemical Research in Toxicology4, 566–571.
107.
Crofton-SleighC., DohertyA., EllardS., ParryE.M., and VenittS. (1993). Micronucleus assays using cytochalasin-blocked MCL-5 cells, a proprietary human cell line expressing five human cytochromes P450 and microsomal hydrolase.Mutagenesis8, 363–372.
108.
MacDonaldC. (1993). Development of new animal cell lines by oncogene immortalisation.The Genetic Engineer and Biotechnologist13, 121–124.
109.
ShimadaT., GillamE.M.J., SandhuP., GuoZ., TukeyR.H., and GuengerichF.P. (1994). Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli: simplified bacterial systems for genotoxicity assays.Carcinogenesis15, 2523–2529.
110.
GuengerichF.P., GillamE.M.J., OhmoriS., SandhuP., BrianW.R., SariM-A., & IwasakiM. (1993). Expression of human cytochrome P450 enzymes in yeast and bacteria and relevance of studies on catalytic activity.Toxicology82, 21–37.
111.
CombesR.D. (1991). Use of clinical samples for biomonitoring of genotoxic exposure to pharmaceuticals. In Clinical Measurement in Drug Evaluation (ed. NimmoW.), pp. 173–191. London: Wolfe Medical Publications.
112.
CombesR.D., AndersonD., BrooksT., NealeS., and VenittS. (1984). The detection of mutagens in urine, faeces and body fluids. In Guidelines for Mutagenicity Testing, Part III, Supplementary Tests, Mutagens in Body Fluids and Excreta, Nitrosation Products, United Kingdom Environmental Mutagen Society (ed. DeanB.J.), pp. 203–244. Swansea: UKEMS.
113.
Di GiorgioC., De MeoM.P., LagetM., GuiraudH., BottaA., and DumenilG. (1994). The micro-nucleus assay in human lymphocytes: screening for inter-individual variability and application to biomonitoring.Carcinogenesis15, 313–317.
114.
AshbyJ. (1993). Precedents or possibilities: which should guide the harmonisation of mutagenicity test protocols and carcinogen prediction strategies?Mutation Research298, 291–295.
115.
GallowayS.M. ed. (1994). Report of the International Workshop on Standardisation of Genotoxicity Test Procedures.Mutation Research312, 195–319.
116.
D'ArcyP.F., and HarronD.W.G. (1994). Proceedings of the Second International Conference on Harmonisation, 763 pp. Belfast, Northern Ireland: Queen's University Press.
117.
TweatsD., and ScalesD. (1994). Progress with harmonisation of guidelines for human pharmaceuticals.Toxicology and Ecotoxicology News1, 113–116.
118.
BenigniR., and GuilianiA. (1988). Predicting carcinogenicity with short-term tests: biological models and operational approaches.Mutation Research205, 227–236.
119.
AshbyJ. (1994). Regulatory requirement for three dose levels and proof of tissue localisation in rodent genetic toxicity assays — a call for supporting data.Mutation Research308, 243–244.
120.
TiceR.R., ErexsonG., HilliardC.J., HustonJ.L., BochmR.M., GulatiD., and ShelbyM.D. (1990). Effect of treatment protocol and sample time on frequencies of micronucleated cells in mouse bone marrow and peripheral blood.Mutagenesis5, 313–321.
121.
TiceR.R., ErexsonG.L., and ShelbyM.D. (1990). The induction of micronucleated and polychromatic erythrocytes in mice using single and multiple treatments.Mutation Research234, 187–193.
122.
van den HeuvalM.J., ClarkD.G., FielderR.J., KoundakjianP.P., OliverG.J.A., PellingD., TomlinsonN.J., and WalkerA.P. (1990). The international validation of a fixed-dose procedure as an alternative to the classical LD50 test.Food and Chemical Toxicology28, 469–482.
123.
McKenzieB. (1992). The questionable relevance of the maximum tolerated dose as the sole basis. for dose selection for carcinogenicity studies: a case study. In The Carcinogenicity Debate (ed. McAuslaneJ.A.N., LumleyC.E., WalkerS.R.), pp. 233–240. Lancaster, UK: Quay Publishing.
124.
AshbyJ. (1994). Dose-level selection for in vivo genetic toxicity assays.Mutation Research311, 165.
125.
MackayJ.M., and ElliottB.M. (1992). Dose-ranging and dose-setting for in vivo genetic toxicology studies.Mutation Research271, 97–99.
126.
FielderR.F., AllenJ.A., BoobisA.R., BothamP.A., DoeJ., EsdaileD.J., GatehouseD.G., Hodson-WalkerG., MortonD.B., KirklandD.J., and RicholdM. (1992). Dose setting in in vivo mutagenicity assays.Mutagenesis7, 313–320.
127.
Anon. (1992). Micronucleus test with mouse peripheral blood erythrocytes by acridine orange supravital staining: the summary report of the 5th collaborative study by CSGMT/JEMS: MMS.Mutation Research278, 83–98.
128.
MadleS., DeanS.W., AndraeU., BrambillaG., BurlinsonB., DoolittleD.J., FurihataC., HertnerT., McQueenC., and MoriH. (1994). Recommendations for the performance of UDS tests in vitro and in vivo.Mutation Research312, 263–285.
129.
HayashiM., MoritaT., KodamaY., SofuniT., & IshidateM.Jr. (1990). The micronucleus assay with mouse peripheral blood reticulocytes, using acridine orange-coated slides.Mutation Research245, 245–249.
130.
KennellyJ.C., WatersR., AshbyJ., LefevreP.A., BurlinsonB., BenfordD.J., DeanS.W., and MitchellI. deG. (1993). In vivo rat UDS assay. In Supplementary Mutagenicity Tests: UKEMS Recommended Procedures, UKEMS Subcommittee Report on Guidelines for Mutagenicity Testing, Part III (Revised) (ed. KirklandD.J., FoxM.), pp. 52–77. Cambridge: Cambridge Univcrsity Press
131.
TungalA., BoninA.M., HeS., and BakerR.S.U. (1991). Micronuclei induction by dichlorvos in the mouse skin.Mutagenesis6, 405–408.
132.
FurihataC., HiroseK., and MatsushimaT. (1991). Genotoxicity and cell proliferative activity of omeprazole in rat stomach mucosa.Mutation Research262, 73–76.
133.
McKelvey-MartinV.I., GreenM.H.L., SchmezerP., Pool-ZobelB.L., DeMeoM.P., and CollinsA. (1993). The single cell gel electrophoresis assay (comet assay): a European perspective.Mutation Research288, 47–63.
134.
MyersB., and ParryJ.M. (1994). The application of the restriction site mutation assay to the study of the induction of mutations in the tissues of rodents.Mutagenesis9, 175–177.
135.
SullivanN., GatehouseD., and TweatsD. (1993). Mutation, cancer and transgenic models: relevance to the toxicology industry.Mutagenesis8, 167–174.
136.
ShortJ.M. ed. (1994). Transgenic Systems in Mutagenesis and Carcinogenesis.Mutation Research307, 427–597.
137.
TennantR.W., HansenL., and SpaldingJ. (1994). Gene manipulation and genetic toxicology.Mutagenesis9, 171–174.
138.
MorrisonV., and AshbyJ. (1994). A preliminary evaluation of the performance of the Muta™ mouse (lacZ) and Big Blue™ (lac I) transgenic mouse mutation assays.Mutagenesis9, 367–375.
139.
AlbaneseR., MirkovaE., GatehouseD., and AshbyJ. (1988). Species-specific response to the rodent carcinogens 1,2-dimethylhydrazine and 1,2-dibromochloropropane in rodent bone marrow micronucleus assays.Mutagenesis3, 35–38.
140.
LefevreP.A., TinwellH., GallowayS.M., HillR., MackayJ.M., ElcombeC.R., FosterJ., RandallV., CallanderR., and AshbyJ. (1994). Evaluation of the genetic toxicity of the peroxisome proliferator and carcinogen methyl clofenapate, including assays using Muta™ and Big Blue™ transgenic mice.Human and Experimental Toxicology13, 764–775.
141.
AshbyJ., and TinwellH. (1994). Use of transgenic mouse lac I/L mutation assays in genetic toxicology.Mutagenesis9, 179–181.
142.
Anon. (1991). Statistics of Scientific Procedures on Living Animals, Great Britain 1990, Cmnd 1574, 49 pp. London: HMSO.
143.
Anon. (1992). Statistics of Scientific Procedures on Living Animals, Great Britain 1991, Cmnd 2023, 49 pp. London: HMSO.
144.
Anon. (1993). Statistics of Scientific Procedures on Living Animals, Great Britain 1992, Cmnd 2356, 49 pp. London: HMSO.
145.
Anon. (1995). Statistics of Scientific Procedures on Living Animals, Great Britain 1993, Cmnd 2746, 50 pp. London: HMSO.
146.
SepulvedaA.R., FinegoldM.J., SmithB., SlagleB.L., DeMayoJ.L., ShenR-F., WooS.L.C., and ButelJ.S. (1989). Development of a transgenic mouse system for the analysis of stages in liver carcinogenesis using tissue-specific expression of SV40 large T-antigen controlled regulatory elements of the human α-1–antitryp-sin gene.Cancer Research49, 6108–6117.
147.
DouglasG., BlakeyD.H., and ClaysonD.B. (1988). Genotoxicity tests as predictors of carcinogens: an analysis.Mutation Research196, 83–93.
148.
CombesR.D. (1994). Mutagenicity testing of cosmetics: current trends and prospects of the replacement, refinement and reduction of animal testing.Comments Toxicology5, 247–270.
149.
BridgesB.A. (1988). Genetic toxicology at the crossroads — a personal view on the development of short-term tests for predicting carcinogenicity.Mutation Research205, 25–31.
